Brainsway Ltd. (BWAY)
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Specialties
BrainsWay Ltd.
1-25 of 280 filings
Recent SEC filings with analysis
- 6-KBrainsWay announced further expansion of U.S.
- 6-KBrainsWay filed a Form 6-K furnishing its notice and proxy statement for the Annual General Meeting of Shareholders to be held November 25, 2026 in Jerusalem,…
- 6-KBrainsWay (NASDAQ & TASE: BWAY) announced a strategic collaboration with Inland Psychiatric Medical Group, an established behavioral health provider serving…
- 6-KBrainsWay announced that favorable insurance coverage for its SWIFT Accelerated Deep TMS protocol has expanded to over 70 million covered lives in the U.S.
- 6-KBrainsWay reported H1 2026 revenue of $32.6 million, up 35% year-over-year, driven by increased sales and leases of its Deep TMS systems.